StreetAlpha.app
Home › Stocks › INCY

Incyte Corp (INCY)

Healthcare
$114.63
▼ −1.07%
LAST CLOSE · NOV 20

Incyte develops and sells prescription medicines, mainly for blood cancers and other conditions. It last closed at $114.63 on Nov 20, down 1.07% on the day. The next earnings report for INCY is expected around Tue, Feb 9, 2027. For the quarter ended Sep 2026, INCY reported EPS of -$3.86 on revenue of $1.56B, with revenue up 14.0% from a year ago. Over its last 8 reports the stock moved an average of 5.1% the session after earnings. Over the last 12 months INCY insiders bought $0 of stock on the open market and sold $67.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is INCY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold INCY.

Key Stats

Last 12 months
Results
Revenue
$6.0B
+24.9% vs a year ago
Net income
$403.4M
−66.1% vs a year ago
EPS (diluted)
$1.96
−66.8% vs a year ago
Gross margin
92.7%
$5.6B gross profit
Valuation
Market cap
$23.4B
203.8M shares
P/E
58.5
Price over 12 month EPS
Price to sales
3.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$3.3B
At Sep 30
Shareholder equity
$5.6B
Shares outstanding
203.8M
At Oct 22
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.0B$3.0BFY2021FY2022: $3.4B$3.4BFY2022FY2023: $3.7B$3.7BFY2023FY2024: $4.2B$4.2BFY2024FY2025: $5.1B$5.1BFY2025

From INCY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 9
Estimated date · Time not announced
Reported EPS
-$3.86
Quarter ended Sep 2026
Year ago EPS
$2.11
−282.9% on a GAAP basis
Revenue
$1.56B
+14.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.95Dec '24Mar 2025: $0.80Mar '25Jun 2025: $2.04Jun '25Sep 2025: $2.11Sep '25Dec 2025: $1.46Dec '25Mar 2026: $1.47Mar '26Jun 2026: $2.81Jun '26Sep 2026: -$3.86Sep '26Latest -$3.86
Revenue by quarter
Dec 2024: $1.18BDec '24Mar 2025: $1.05BMar '25Jun 2025: $1.22BJun '25Sep 2025: $1.37BSep '25Dec 2025: $1.51BDec '25Mar 2026: $1.27BMar '26Jun 2026: $1.67BJun '26Sep 2026: $1.56BSep '26Latest $1.56B
How INCY moved after its last 8 reports
Average move the session after a report ±5.1%
Oct 29, 2026Time not announced−0.1%
Jul 28, 2026Time not announced+9.3%
Apr 28, 2026Time not announced+2.1%
Feb 10, 2026Time not announced−8.2%
Oct 28, 2025Time not announced−1.5%
Jul 29, 2025Time not announced+10.3%
Apr 29, 2025Time not announced+1.5%
Feb 10, 2025Time not announced−7.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on INCYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on INCY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on INCY

Technical Analysis

INCY · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 4% below its 20 day and 3% below its 50 day average. It is 5% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Jul 23) at $114.50, and the nearest resistance the Pivot at $115.47.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 3.2%/day
Key levels
$132.6052 week high+15.7%
$120.04100 day average+4.7%
$118.8420 day average+3.7%
$118.4950 day average+3.4%
$117.17Swing high (Oct 22)+2.2%
$116.66Pivot R1+1.8%
$115.47Pivot+0.7%
$114.62Last close
$114.50Swing low (Jul 23)−0.1%
$113.43Pivot S1−1.0%
$109.31200 day average−4.6%
$89.2552 week low−22.1%
Indicators
RSI (14)41.69Middle of its rangeNeutral
MACD-0.04Below its signal lineBearish
Stochastic14.8Near the bottom of its rangeOversold
ADX (14)11.1No clear trend
Williams %R-96.4Oversold below −80, overbought above −20Oversold
CCI (20)-105.9Oversold below −100, overbought above 100Oversold
Rate of change−4.2%Change over 10 sessionsBearish
ATR (14)$3.64Typical daily range, 3.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for INCY

What happened before

See how INCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow INCY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How INCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for INCYHow many large options trades hit INCY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

INCY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲505 buying vs 350 selling
  • ▼Held by funds -1.2 pts
  • ▲Funds holding +42
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.75 to 4.28
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding905863+4.9%
In funds' top 101113−15.4%
Held by funds98.3%99.5%−1.2 pts
New / increased135 / 370117 / 358+6.3%
Reduced / sold out269 / 81273 / 75+0.6%
Put/call ratio4.280.75+469.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INCY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

INCY Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$67.8M29 sales · 8 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $8.9M2026-01 sold $2.8M2026-02 sold $1.9M2026-03 sold $1.8M2026-04 sold $1.8M2026-05 sold $1.6M2026-06 sold $264K2026-07 sold $5.4M2026-08 sold $10.0M2026-09 sold $2.8M2026-10 sold $298K2026-11 sold $30.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Pablo J CagnoniPresident, Global Head of R&DSale plan2,642$120.96$320K
Nov 16Steven H SteinCMO & Head of Late-Stage Dev.Sale plan576$121.98$70K
Nov 13Lee HeesonEVP, Head of Incyte IntlSale plan10,694$120.82$1.3M
Nov 6Steven H SteinCMO & Head of Late-Stage Dev.Sale plan240,193$118.39$28.4M
Nov 3Thomas TrayPrincipal Accounting OfficerSale plan610$118.96$73K
Oct 15Pablo J CagnoniPresident, Global Head of R&DSale plan2,642$112.71$298K
Every insider buy and sale for INCY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See INCY insider trades →

From SEC Form 4 filings by INCY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

INCY Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
—
 
Left in program
—
 
Shares outstanding, 12 months
+3.8%
More shares
Last quarter
—
Sep 2026
Avg price paid, last quarter
—
 
S&P 500 rank by spending
—
 
Spent each quarter, last 3 yearsTop bar $2.0B
Dec 2023: $0Mar 2024: $0Jun 2024: $2.0B, average price $60.00Sep 2024: $0Dec 2024: $0Mar 2025: $0Jun 2025: $0Sep 2025: $0Dec 2025: $0Mar 2026: $0Jun 2026: $0Sep 2026: $0
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 29, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INCY is in one of them and how their past INCY trades turned out.

INCY in the AI portfolios
Loading…

INCY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INCY in an article yet. Here's the latest on the wider market.

INCY in the news

INCY Congress Trades

All congress trades →
Trades, 12 months
2
Buys
1
50%
Sells
1
50%
People
1
Last filed Nov 5
Who traded INCY · since 2014
Latest 5 filings of 9
$1K – $15KTraded Oct 7, 2026Filed Nov 5, 2026
$1K – $15KTraded Sep 4, 2026Filed Oct 7, 2026
$1K – $15KTraded May 15, 2025Filed May 31, 2025
$1K – $15KTraded Mar 6, 2023Filed Apr 17, 2023
$1K – $15KTraded Dec 22, 2020Filed Jan 11, 2021
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CASell$1K – $15KOct 7, 2026Nov 5, 202629 d
Ro KhannaD · CABuy$1K – $15KSep 4, 2026Oct 7, 202633 d
Rob BresnahanR · PASell$1K – $15KMay 15, 2025May 31, 202516 d
Dan GoldmanD · NYSell$1K – $15KMar 6, 2023Apr 17, 202342 d
Gilbert CisnerosD · CASell$1K – $15KDec 22, 2020Jan 11, 202120 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Incyte

Incyte is a biopharmaceutical company based in Wilmington, Delaware. It discovers, develops and sells prescription medicines, mainly for blood cancers and other conditions, including a topical cream. Physicians prescribe its products to patients, and insurers and other payors decide on coverage. Some of its products are also developed and sold with partners, including Novartis and Lilly.

Headquarters
Wilmington, DE
Founded
2001